Flaherty KR, Wells AU, Cottin V, et al. - In this double-blind, placebo-controlled, phase 3 trial carried out in 15 countries, researchers randomized 663 individuals with fibrosing lung disease impacting more than 10% of lung volume on high-resolution CT to receive nintedanib at a dose of 150 mg twice daily or placebo in order to determine the efficiency of nintedanib in a broad spectrum of fibrosing lung diseases. The most prevalent adverse event was diarrhea, as reported in 66.9% and 23.9% of patients treated with nintedanib and placebo, respectively. In the nintedanib group vs placebo group, abnormalities on liver-function testing were more prevalent. Hence, the annual rate of decrease in the forced vital capacity in patients with progressive fibrosing interstitial lung diseases was significantly lower in individuals who received nintedanib in comparison with those who received placebo; diarrhea was a general adverse event.